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Abstract
Oxygen is one of the most commonly used therapeutic agents.
Injudicious use of oxygen at high partial pressures (hyperoxia) for
unproven indications, its known toxic potential, and the
acknowledged roles of reactive oxygen species in tissue injury led
to skepticism regarding its use. A large body of data indicates that
hyperoxia exerts an extensive profile of physiologic and pharmaco-
logic effects that improve tissue oxygenation, exert anti-inflamma-
tory and antibacterial effects, and augment tissue repair mecha-
nisms. These data set the rationale for the use of hyperoxia in a list
of clinical conditions characterized by tissue hypoxia, infection, and
consequential impaired tissue repair. Data on regional hemo-
dynamic effects of hyperoxia and recent compelling evidence on its
anti-inflammatory actions incited a surge of interest in the potential
therapeutic effects of hyperoxia in myocardial revascularization and
protection, in traumatic and nontraumatic ischemic-anoxic brain
insults, and in prevention of surgical site infections and in
alleviation of septic and nonseptic local and systemic inflammatory
responses. Although the margin of safety between effective and
potentially toxic doses of oxygen is relatively narrow, the ability to
carefully control its dose, meticulous adherence to currently
accepted therapeutic protocols, and individually tailored treatment
regimens make it a cost-effective safe drug.
Oxygen is one of the most widely used therapeutic agents. It
is a drug in the true sense of the word, with specific bio-
chemical and physiologic actions, a distinct range of effective
doses, and well-defined adverse effects at high doses.
Oxygen is widely available and commonly prescribed by
medical staff in a broad range of conditions to relieve or
prevent tissue hypoxia. Although oxygen therapy remains a
cornerstone of modern medical practice and although many
aspects of its physiologic actions have already been eluci-
dated, evidence-based data on its effects in many potentially
relevant clinical conditions are lagging behind.
The cost of a single use of oxygen is low. Yet in many
hospitals, the annual expenditure on oxygen therapy exceeds
those of most other high-profile therapeutic agents. The easy
availability of oxygen lies beneath a lack of commercial
interest in it and the paucity of funding of large-scale clinical
studies on oxygen as a drug. Furthermore, the commonly
accepted paradigm that links hyperoxia to enhanced oxidative
stress and the relatively narrow margin of safety between its
effective and toxic doses are additional barriers accounting
for the disproportionately small number of high-quality studies
on the clinical use of oxygen at higher-than-normal partial
pressures (hyperoxia). Yet it is easy to meticulously control
the dose of oxygen (the combination of its partial pressure
and duration of exposure), in contrast to many other drugs,
and therefore clinically significant manifestations of oxygen
toxicity are uncommon. The present review summarizes
physiologic and pathophysiologic principles on which oxygen
therapy is based in clinical conditions characterized by
impaired tissue oxygenation without arterial hypoxemia.
Application
Normobaric hyperoxia (normobaric oxygen, NBO) is applied
via a wide variety of masks that allow delivery of inspired
oxygen of 24% to 90%. Higher concentrations can be delivered
via masks with reservoirs, tightly fitting continuous positive
airway pressure-type masks, or during mechanical ventilation.
There are two methods of administering oxygen at pressures
higher than 0.1 MPa (1 atmosphere absolute, 1 ATA) (hyper-
baric oxygen, HBO). In the first, a small hyperbaric chamber,
usually designed for a single occupant, is used. The chamber
is filled with 100% oxygen, which is compressed to the
pressure required for treatment. With the second method, the
treatment is given in a large multiplace hyperbaric chamber.
The chamber is filled with compressed air while the patients
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breathe 100% oxygen at the same ambient pressure via a
mask or hood (Figure 1) [1].
Tissue oxygenation
Delivery of oxygen to tissues depends on adequate ventila-
tion, gas exchange, and circulatory distribution. When air is
breathed at normal atmospheric pressure, most of the oxygen
is bound to hemoglobin while only very little is transported
dissolved in the plasma. On exposure to hyperoxia, hemo-
globin is completely saturated with oxygen. This accounts for
only a small increase in arterial blood oxygen content. In
addition, the amount of physically dissolved oxygen in the
blood also increases in direct proportion to the ambient
oxygen partial pressure. Due to the low solubility of oxygen in
blood, the amount of dissolved oxygen in arterial blood
attainable during normobaric exposures to 100% oxygen
(about 2 vol%) can provide only one third of resting tissue
oxygen requirements. However, on exposure to oxygen at a
pressure of three atmospheres (in a hyperbaric chamber),
there is sufficient oxygen dissolved in the plasma (about 6
vol%) to meet the average requirements of resting tissues by
means of dissolved oxygen alone without contribution from
oxygen bound to hemoglobin [1,2]. This is part of the
rationale behind the use of hyperoxia in situations in which
the hemoglobin’s oxygen-carrying capacity has been impaired
(for example, in carbon monoxide poisoning [3] and in severe
anemia when transfusion of blood is not possible [1]).
Deliberations on the effect of hyperoxia on the availability of
molecular oxygen to tissues which are based on changes in
arterial blood oxygen content undervalue the main effect of
hyperoxia that is related to changes in its partial pressure in
the blood (Table 1). The flow of oxygen into tissues occurs by
diffusion. The driving force for diffusion of oxygen is
determined by its partial pressure gradient between capillary
blood and tissue cells and much less so by increased oxygen
content [4]. Inhalation of 100% oxygen yields a 5- to 7-fold
increase in arterial blood oxygen tension at normal atmos-
pheric pressure and may reach values close to 2,000 mm Hg
during hyperbaric exposure to oxygen at 0.3 MPa (3 ATA).
The marked increase in oxygen tension gradient from the
blood to metabolizing cells is a key mechanism by which
hyperoxygenation of arterial blood can improve effective
cellular oxygenation even at low rates of tissue blood flow.
A recent surge of interest in the value of increasing the
availability of oxygen to tissues in critical conditions yielded
important studies like the one on early goal-directed therapy
in sepsis [5] that assessed a resuscitation protocol aimed at
increasing tissue oxygenation. Regrettably, the specific value
of oxygen therapy was not assessed in this study. Yet a
recent study that compared the influence of allogeneic red
blood cell transfusion with 100% oxygen ventilation in
volume-resuscitated anemic patients after cardiac surgery
demonstrated a superior effect of normobaric hyperoxia
(NBO) on tissue (skeletal muscle) oxygen tension [6].
Hemodynamic effects
The availability of oxygen to tissues is also determined by its
effects on hemodynamic variables. In healthy animals and
humans, oxygen causes a temporary increase in blood
pressure by increasing total peripheral vascular resistance
secondary to systemic peripheral vasoconstriction [7]. This
transient change is rapidly counterbalanced by a decrease in
heart rate and cardiac output that prevents a sustained effect
on arterial blood pressure [7]. The unique combination of
hyperoxia-induced vasoconstriction and high blood oxygen
tension affords an advantage by decreasing a vasogenic
component of increased tissue hydrostatic pressure while
preserving a high blood-to-tissue oxygen partial pressure
gradient and is therefore considered beneficial in crush injury
and compartment syndrome [8] as well as brain edema,
particularly when the latter develops in situations in which
additional indications for HBO therapy exist, such as carbon
monoxide poisoning and air embolism [9].
Figure 1
A multiplace walk-in hyperbaric chamber. The treatment pressure is
attained by compressing the ambient air in the chamber. Patients are
exposed to oxygen or other gas mixtures at the same pressure via
masks or hoods. Many hyperbaric facilities are equipped for providing
a full-scale critical care environment, including mechanical ventilation
and state-of-the-art monitoring.
Table 1
Alveolar oxygen partial pressure while breathing air or 100%
oxygen at different ambient pressures from 1 to 3 ATA
Total pressure
PAO2 PAO2 on
ATA mm Hg on air 100% O2
1 760 102 673
2.5 1,900 342 1,813
3 2,280 422 2,193
ATA, atmosphere absolute; PAO2, alveolar oxygen partial pressure.Recent experimental evidence supports the role of hyperoxia
in cerebral ischemic-anoxic insults such as stroke, head
injury, near drowning, asphyxia, and cardiac arrest [10]. In the
specific case of traumatic brain injury, it has repeatedly been
shown that, although HBO causes cerebral vasoconstriction,
it increases brain tissue pO2 (partial pressure of oxygen) and
restores mitochondrial redox potential [11,12]. NBO has also
been shown to decrease intracranial pressure and improve
indices of brain oxidative metabolism in patients with severe
head injury [13].
A significant body of experimental data that suggested
beneficial effects of hyperoxia in ischemic stroke was
followed by clinical trials [14-16] that failed to demonstrate
clear-cut benefits. Yet significant shortcomings of the
available clinical data call for re-evaluation of the effect of
hyperoxia on the outcome of stroke and on the possibility to
use it to extend the narrow therapeutic time window for
stroke thrombolysis [17].
Another area of controversy is the use of NBO in asphyxiated
newborn infants. Initial laboratory and clinical studies
suggested an inferior effect of resuscitation with 100%
oxygen compared with room air [18,19]. Later cumulative
clinical experience [20,21] and systematic review of the litera-
ture [22] have not indicated a significant difference in the
effectiveness of either gas source or in the final outcome in
this specific group of patients. Yet a recent systematic review
and meta-analysis of the few available randomized or
quasirandomized studies of depressed newborn infants have
shown a significant reduction in the risk of mortality and a
trend toward a reduction in the risk of severe hypoxic ische-
mic encephalopathy in newborns resuscitated with 21%
oxygen [23]. Taken together, the available data definitely do
not support an overall beneficial effect of hyperoxia in this
condition, although the superiority of room air in neonatal
resuscitation may still be regarded as controversial.
In contrast to the knowledge on the effects of hyperoxia on
central hemodynamics, much less is known about its effects
on regional hemodynamics and microhemodynamics. Studies
that looked at hyperoxia-induced changes in regional
hemodynamics in healthy animals both in normal atmospheric
pressure [24-30] and in hyperbaric conditions [24-
26,28,31,32] yielded conflicting results, indicating an
increase, a decrease, or no change in regional blood flows to
specific vascular beds. Only limited and scattered information
on regional hemodynamic effects of hyperoxia in relevant
models of disease is available. In this regard, a study in an
acute canine model of ischemia and reperfusion (IR) of the
external iliac artery showed that HBO did not induce
vasoconstriction in the affected regional vascular bed until
oxygen deficit was corrected [33]. Such findings support
suggestions that a dynamic situation may exist in which
vasoconstriction is not always effective in severely hypoxic
tissues and therefore may not limit the availability of oxygen
during hyperoxic exposures and that hyperoxic vaso-
constriction may resume after correction of the regional
hypoxia. Furthermore, in a severe rat model of hemorrhagic
shock, we have shown that normobaric hyperoxia increased
vascular resistance in skeletal muscle and did not change
splanchnic and renal regional resistances. This yielded
redistribution of blood flow to the small intestine and kidneys
‘at the expense’ of skeletal muscle [34]. A similar divergent
effect of normobaric hyperoxia that augmented hind-quarter
vascular resistance without a significant effect on the superior
mesenteric bed was also found in a rat model of splanchnic
IR [35]. In this regard, NBO-induced redistribution of cardiac
output to the hepatosplanchnic regions was recently reported
in a pig model of severe sepsis [36]. NBO was also shown to
redistribute blood flow to ischemic myocardium and improve
contractile function during low-flow myocardial ischemia [37].
So the claim that hyperoxia is a universal vasoconstrictor in all
vascular beds is an oversimplification both in normal and
pathologic states. Furthermore, understanding of the effects
of hyperoxia on regional hemodynamics cannot be based on
simple extrapolations from healthy humans and animals and
warrants careful evaluation in selected clinical states and
their animal models.
Effects on inflammation
Tissue hypoxia activates a large variety of vascular and inflam-
matory mediators that trigger local inflammation [38] and may
lead to a systemic inflammatory response (SIR) that in many
cases culminates in multiple organ dysfunction and multiple
organ failure (MOF) [39,40]. The wish to prevent or treat
hypoxia-induced inflammatory responses yielded studies that
evaluated the effects of hyperoxia on the microvascular-
inflammatory response. Most of the attention focused on
models of IR which frequently provoke local inflammatory
response, SIR, and MOF [40]. The potential beneficial effects
of hyperoxia are confronted by the understanding of the
central role of reactive oxygen species (ROS) in IR injury
[40-42]. The demonstration of increased production of ROS
during exposure of normal tissues to hyperoxia evoked
concerns that oxygen therapy could exacerbate IR injury. The
seemingly rational unease related to the use of hyperoxia in IR
must be weighed against a gradually growing body of
evidence on beneficial effects of hyperoxia in diverse IR
models [42]. Hyperoxia appears to exert a simultaneous
effect on a number of steps in the proinflammatory cascades
after IR, including interference with polymorphonuclear
leukocyte (PMNL) adhesion and production of ROS. In this
regard, HBO has been shown to decrease rolling and
adhesion of PMNL in the microcirculation following IR of
skeletal muscle [43,44], small bowel [35,45], skin flaps [46],
heart [47,48], and liver [49,50] as well as after carbon
monoxide poisoning [51].
It has been demonstrated by Thom [51] that HBO inhibits
PMNL adherence mediated by β2 integrin glycoproteins
CD11/CD18 by impairing cGMP (cyclic guanosine mono-
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also reduces the expression of the endothelial adhesion
molecules E-selectin [53,54] and ICAM-1 (intracellular
adhesion molecule-1) [42,52]. Hyperoxia is known to affect
the production of nitric oxide (NO) mostly by inducing eNOS
(endothelial NO synthase) protein production [55]. Increased
NO levels may inhibit PMNL adhesion by inhibition of CD18
function and downregulation of endothelial adhesion mole-
cule synthesis [55,56]. Furthermore, it has been shown in
ischemic skin flaps that hyperoxia increases local endothelial
surface superoxide dismutase activity [46]. This action may
diminish the more distal proinflammatory events initiated by
ROS after IR, and indeed HBO has been shown to decrease
lipid peroxidation and oxidative stress in a number of IR
models [49,51,57,58].
HBO was also shown to exert beneficial effects in other
inflammatory conditions, including experimental colitis [59,60],
Crohn disease [61], carrageenan-induced paw edema [62],
and zymossan-induced SIR [63,64]. Detailed mechanisms of
the salutary effects of hyperoxia in some of these conditions
have not yet been fully elucidated.
In addition to a predominant hyperacute proinflammatory
response orchestrated mostly by its effects on PMNLs and
macrophages, tissue hypoxia has been shown to provoke
subsequent anti-inflammatory responses in macrophages
[65-68], to downregulate proinflammatory anti-bacterial func-
tions of T cells via augmented HIF-1a (hypoxia inducible
factor-1a) activity [69], and to weaken local hypoxia-driven
and adenosine A2A receptor-mediated pulmonary anti-inflam-
matory mechanisms [70]. These observations may represent
important subacute effects of hypoxia that help to harness an
initial powerful and potentially destructive proinflammatory
effect, may be a part of tissue repair processes, or may be an
important component of a hypoinflammatory response mani-
fested by some patients with sepsis and acute respiratory
distress syndrome (ARDS).
All in all, the ameliorating effects of hyperoxia on the acute net
proinflammatory response after IR and other conditions may
be related to direct inhibitory effects of oxygen on mecha-
nisms that enhance PMNL rolling, adhesion, activation, and
transmigration to tissues. Hyperoxia may also exert indirect
effects on the inflammatory response simply by ameliorating
tissue hypoxia – a key trigger of inflammation [38]. The
effects of hyperoxia on subsequent stages of tissue res-
ponses to hypoxia and especially on the anti-inflammatory arm
of that response await clarification.
Sepsis is one of the most common clinical causes of SIR. In a
study of early hyperdynamic porcine septic shock, Barth and
colleagues [36] demonstrated beneficial effects of NBO on
apoptosis in the liver and the lungs, on metabolic acidosis,
and on renal function. We found a dose-related beneficial
effect of NBO (100% oxygen for 6 hours per day) on the
pulmonary inflammatory response in sepsis induced by cecal
ligation and puncture (CLP) in rats [71]. Buras and colleagues
[72] studied the effects of hyperoxia at 1, 2.5, and 3 ATA
applied for 1.5 hours twice a day on survival in a mouse CLP
model of sepsis and reported that HBO at 2.5 ATA improved
survival. They also presented data suggesting that augmented
production of the anti-inflammatory cytokine interleukin-10 may
be an important mechanism of the salutary effects of HBO in
this model [72]. The steadily growing body of data on
beneficial effects of hyperoxia in severe local and systemic
inflammation warrants appropriate clinical studies to define its
role as a clinically relevant modifier of hyperinflammation.
Effects on microorganisms and tissue repair
mechanisms
HBO has been studied and used in a large variety of
infections for over 40 years. Early demonstrations of its
beneficial effects in clostridial myonecrosis (gas gangrene)
[73] and in chronic refractory osteomyelitis [74] were
followed by a large body of experimental data on in vitro
effects of increased ambient oxygen partial pressures on
microorganisms and reports on in vivo effects of HBO in
infection [75,76]. HBO exerts direct bacteriostatic and
bactericidal effects mostly on anaerobic microorganisms.
These effects have been attributed to deficient defense
mechanisms of anaerobic microorganisms against increased
production of ROS in hyperoxic environments. Beyond a
direct activity against microorganisms, HBO has been shown
to re-establish defense mechanisms that are critically impaired
by the typically hypoxic microenvironment in infectious sites
[77]. Both phagocytosis and microbial killing by PMNLs are
severely impaired in hypoxic environments. By increasing
tissue oxygen tensions, HBO therapy restores phagocytosis
and augments the oxidative burst that is needed for leukocyte
microbial killing. Furthermore, the activity of a number of
antibiotics is impaired in hypoxic environments and is
restored and even augmented during exposure to HBO.
Other important beneficial effects of hyperoxia in infection are
attributed to enhancement of key components of tissue repair
such as necrotic tissue proteolysis, fibroblast proliferation,
collagen deposition and angiogenesis, migration of epithelial
cells, and bone remodeling by osteoblastic/osteoclastic
activity, which are all severely impaired in hypoxic tissues
[78]. Altogether, direct activity on bacteria (for example,
pseudomonas, some strains of Escherichia, and Clostridium
perfringens), improvement of cellular defense mechanisms,
synergistic effects on antibiotic activity, modulation of the
immune response, and augmentation of mechanisms of tissue
repair form the basis for the use of HBO as adjunctive
therapy in combination with antibiotics and surgery for
treating tissue infections involving both anaerobic and
aerobic microorganisms in hypoxic wounds and tissues [75-
78] and in sepsis-induced SIR [79].
As for normobaric hyperoxia, two recent prospective rando-
mized clinical studies reported significant beneficial effects of
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oxygen at normal atmospheric pressure) on surgical site
infection (SSI) after elective colorectal surgery [80,81]. A
third study [82] on patients undergoing various open
abdominal procedures reported a higher incidence of SSI in
the higher oxygen group and ignited a yet unsettled debate
on the routine use of normobaric hyperoxia to prevent SSI.
Hyperoxia has also been shown to inhibit the growth of some
fungi [83-85] and to potentiate the antifungal effect of amph-
thericin B [84]. Data from case reports, small groups of
patients, and compilations of previous reports support the
use of adjunctive HBO treatment together with amphotericin
B and surgery in invasive rhinocerebral mucormycosis
[85-87]. The level of evidence on the effects of HBO in other
fungal infections is less compelling.
The proven pathophysiologic profile of actions of hyperoxia
set the basis for its use in selected clinical conditions.
Sufficient clinical evidence is available for the use of HBO in
carbon monoxide poisoning, decompression sickness, arterial
gas embolism, radiation-induced tissue injury, clostridial myo-
necrosis, problem wounds, crush injury, and refractory osteo-
myelitis [1]. Effects of NBO in these and in other potentially
relevant clinical states are much less studied. Studies that
evaluate a range of oxygen doses in both the normobaric and
hyperbaric pressure range are largely unavailable and should
be encouraged by appropriate allocation of research funding.
Toxicity
The major limitation confronting a much more liberal clinical
use of hyperoxia is its potential toxicity and the relatively
narrow margin of safety that exists between its effective and
toxic doses. However, an awareness of the toxic effects of
oxygen and an acquaintance with safe pressure and duration
limits of its application, combined with the ability to carefully
manage its dose, provide an acceptable basis for expanding
the current list of clinical indications for its use. The most
obvious toxic manifestations of oxygen are those exerted on
the respiratory system and central nervous system (CNS)
[88].
Oxygen toxicity is believed to result from the formation of
ROS in excess of the quantity that can be detoxified by the
available antioxidant systems in the tissues. Although mecha-
nisms of free radical damage to a substantial array of cellular
systems (proteins, enzymes, membrane lipids, and nucleic
acids) have already been characterized [88-90], large gaps
exist in our understanding of the intermediate stages in the
pathophysiologic cascades that follow such reactions and
result in functional deficits and clinical phenomena.
The lungs are exposed to higher oxygen tensions than any
other organ. At exposures to ambient oxygen pressures of up
to 0.1 MPa (1 ATA), the lungs are the first organ to respond
adversely to the toxic effects of oxygen. The response
involves the entire respiratory tract, including the airway
epithelium, microcirculation, alveolar septa, and pleural
space. Pulmonary oxygen toxicity is characterized by an initial
period in which no overt clinical manifestations of toxicity can
be detected – termed the ‘latent period’. The duration of this
‘silent’ clinical interval is inversely proportional to the level of
inspired oxygen [90,91].
Acute tracheobronchitis is the earliest clinical syndrome that
results from the toxic effects of oxygen on the respiratory
system. It does not develop in humans breathing oxygen at
partial pressures of below 0.05 MPa (0.5 ATA or 50% oxygen
at normal atmospheric pressure). In healthy humans breathing
more than 95% oxygen at normal atmospheric pressure
(0.1 MPa), tracheobronchitis develops after a latent period of
4 to 22 hours and may occur as early as 3 hours while
breathing oxygen at 0.3 MPa (3 ATA) [90,92,93]. It can start
as a mild tickling sensation, later followed by substernal
distress and inspiratory pain, which may be accompanied by
cough and, when more severe, by a constant retrosternal
burning sensation. Tenacious tracheal secretions may accu-
mulate. Upon termination of hyperoxic exposure, the symp-
toms subside within a few hours, with complete resolution
within a few days [90,92,93].
Longer exposures to oxygen (usually more than 48 hours at
0.1 MPa) may induce diffuse alveolar damage (DAD). The
clinical symptoms as well as the laboratory, imaging, and
pathologic findings of oxygen-induced DAD are not
significantly different from those of ARDS from other causes
[94]. Resolution of the acute phase of pulmonary oxygen
toxicity or prolonged exposures to oxygen at sublethal con-
centrations such as during prolonged hyperoxic mechanical
ventilation may result in a chronic pulmonary disease
characterized by marked residual pulmonary fibrosis and
emphysema with tachypnea and progressive hypoxemia
[94,95]. The relative contributions of hyperoxia, the under-
lying clinical condition, and mechanical ventilation to the
occurrence of chronic pulmonary fibrosis and emphysema in
human adults have yet to be clarified.
CNS oxygen toxicity occurs in humans at much higher oxygen
pressures, above 0.18 MPa (1.8 ATA) in water and above
0.28 MPa (2.8 ATA) in dry exposures in a hyperbaric chamber.
Hence, CNS toxicity does not occur during normobaric
exposures but is the main limitation for the use of HBO in
diving and hyperbaric treatments. The ‘latent’ duration until
the appearance of symptoms of CNS oxygen toxicity is
inversely related to the oxygen pressure. It may last for more
than 4 hours at 0.17 to 0.18 MPa and may be as short as
10 minutes at 0.4 to 0.5 MPa.
The most dramatic manifestation of CNS oxygen toxicity is a
generalized tonic-clonic (grand mal) seizure [96]. Hyperoxia-
induced seizures are believed to be reversible, causing no
residual neurologic damage and disappearing upon reduction
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changes in cortical electrical activity were reportedly seen on
exposure to HBO a few minutes prior to the full development
of the electrical discharges [97]. Unfortunately, no real-time
on-line definition of the preseizure electroencephalogram
(EEG) activity which could serve as an early EEG indicator of
CNS oxygen toxicity is available [98].
Other symptoms of CNS toxicity include nausea, dizziness,
sensation of abnormality, headache, disorientation, light-
headedness, and apprehension as well as blurred vision,
tunnel vision, tinnitus, respiratory disturbances, eye twitching,
and twitching of lips, mouth, and forehead. CNS toxicity does
not appear to have warning signs as there is no consistency
in the pattern of appearance of symptoms and no typical
gradual sequence of minor signs appearing prior to the full
development of the seizures [88].
The most dramatic personal factor that may modify the sensi-
tivity to CNS oxygen toxicity is an increase in blood pCO2
(partial pressure of carbon dioxide) [99,100]. Hypercapnia
occurs in patients due to hypoventilation, chronic lung
diseases, effects of analgesics, narcotics, other drugs, and
anesthesia and should be taken into consideration in
designing individual hyperoxic treatment protocols. Various
pharmacologic strategies were tested in animal models for
postponing hyperoxic-induced seizures. However, none of
them has shown clinically relevant efficacy [88].
Reversible myopia is a relatively common manifestation of the
toxic effects of HBO on the lens [88]. Cataract formation has
been reported after numerous HBO sessions and is not a real
threat during standard protocols. Other possible side effects
of hyperbaric therapy are related to barotraumas of the
middle ear, sinuses, teeth, or lungs which may result from
rapid changes in ambient hydrostatic pressures that occur
during the initiation and termination of treatment sessions in a
hyperbaric chamber. Proper training of patients and careful
adherence to operating instructions decrease the incidence
and severity of hyperbaric chamber-related barotraumas to an
acceptable minimum.
Due to its potential toxic effects, HBO is currently restricted
to short sessions (less than 2 hours), at pressures below the
threshold of CNS toxicity (0.28 MPa), with ‘recovery’ breaks
of few minutes during which the patient is switched to air
breathing at the treatment pressure [1]. As for NBO, when-
ever possible, it should be restricted to periods shorter than
the latent period for development of pulmonary toxicity. When
used according to currently employed standard protocols,
oxygen therapy is extremely safe.
Conclusions
This review summarizes the unique profile of physiologic and
pharmacologic actions of oxygen that set the basis for its use
in human diseases. In contrast to a steadily growing body of
mechanistic data on hyperoxia, the accumulation of high-
quality information on its clinical effects lags behind. The
current list of evidence-based indications for hyperoxia is
much narrower than the wide spectrum of clinical conditions
characterized by impaired delivery of oxygen, cellular hypoxia,
tissue edema, inflammation, infection, or their combination
that could potentially be alleviated by oxygen therapy. Further-
more, most of the available reasonably substantiated clinical
data on hyperoxia originate from studies on HBO which
usually did not control for the effects of NBO.
The easy availability of normobaric hyperoxia calls for a much
more vigorous attempt to characterize its potential clinical
efficacy. The multifaceted beneficial profile of actions of
hyperoxia warrants an appropriately funded traditional
pharmacologic research approach that will determine the
efficacy of a range of safe nontoxic doses (combinations of
partial pressure and duration) of hyperoxia in a prospective
blinded fashion.
Competing interests
The author declares that they have no competing interests.
References
1. Tibbles PM, Edelsberg JS: Hyperbaric-oxygen therapy. N Engl J
Med 1996, 334:1642-1648.
2. Borema I, Meyne NG, Brummelkamp WK, Bouma S, Mensch MH,
Kamermans F, Stern Hanf M, van Aalderen W: Life without
blood. Ned Tijdschr Geneeskd 1960, 104:949-954.
3. Weaver LK, Jopkins RO, Chan KJ, Churchill S, Elliot CG,
Clemmer TP, Orme JF, Thomas FO, Morris AH: Hyperbaric
oxygen for acute carbon monoxide poisoning. N Engl J Med
2002, 347:1057-1067.
4. Weibel ER: Delivering oxygen to the cells. In The Pathway for
Oxygen. Edited by Weibel ER. Boston: Harvard University Press;
1984:175-210.
5. Rivers EP, Ander DS, Powell D: Early goal-directed therapy in
the treatment of severe sepsis and septic shock. N Engl J
Med 2001, 345:1368-1377.
6. Suttner S, Piper SN, Kumle B, Lang K, Rohn KD, Isgro F, Boldt J:
The influence of allogeneic red blood cell transfusion com-
pared with 100% oxygen ventilation on systemic oxygen
transport and skeletal muscle oxygen tension after cardiac
surgery. Anesth Analg 2004, 99:2-11.
7. Lambertsen CJ: Effects of oxygen at high partial pressure. In
Handbook of Physiology: Respiration. Section 3, volume 2.
Edited by Fenn WO, Rahn H. Bethesda, MD: American Physio-
logical Society; 1965:1027-1046.
8. Bouachour G, Cronier P, Gouello, Toulemonde JL, Talha A,
Alquier P: Hyperbaric oxygen therapy in the management of
crush injuries: a randomized double blind placebo-controlled
clinical trial. J Trauma 1996, 41:333-339.
9. Sukoff MH, Ragatz RE: Hyperbaric oxygenation for the treat-
ment of acute cerebral edema. Neurosurg 1982, 10:29-38.
Critical Care    Vol 13 No 1 Bitterman
Page 6 of 8
(page number not for citation purposes)
This article is part of a review series on 
Gaseous mediators, 
edited by Peter Radermacher.
Other articles in the series can be found online at
http://ccforum.com/series/gaseous_mediators10. Nemoto EM, Betterman K: Basic physiology of hyperbaric
oxygen in brain. Neurosurg Res 2007, 29:116-126.
11. Daugherty WP, Levasseur JE, Sun D, Rockswold GL, Bullock R:
Effect of hyperbaric oxygen therapy on cerebral oxygenation
and mitochondrial function following moderate lateral fluid-
percussion injury in rat. J Neurosurg 2004, 101:499-504.
12. Rockswold SB, Rockswold GL, Defillo A: Hyperbaric oxygen in
traumatic brain injury. Neurosurg Res 2007, 29:162-172.
13. Tolias CM, Reinert M, Seiler R, Gilman C, Scharf A, Bullock MR:
Normobaric hyperoxia-induced improvement in cerebral
metabolism and reduction in intracranial pressure in patients
with severe brain injury. J Neurosurg 2004, 101:435-444.
14. Anderson DC, Bottini AG, Jagiella WM, Westphal B, Ford S,
Rockswold GL, Loewenson RB: A pilot study of hyperbaric
oxygen in the treatment of human stroke. Stroke 1991, 22:
1137-1142.
15. Nighoghossian N, Trouillas P, Adeleine P, Salord E: Hyperbaric
oxygen in the treatment of acute ischemic stroke. A double
blind pilot study. Stroke 1995, 26:1369-1372.
16. Rusyniac DE, Kirk MA, May JD, Kao LW, Brizendine EJ, Welch JL,
Cordell WH, Alonso R: Hyperbaric oxygen therapy in acute
ischemic stroke: results of the hyperbaric oxygen in acute
ischemic stroke trial pilot study. Stroke 2003, 34:571-574.
17. Singhal AB: Oxygen therapy in stroke: past, present and
future. Int J Stroke 2006 4:191-200.
18. Saugstad OD: Resuscitation with room air or oxygen supple-
mentation. Clin Perinatol 1998, 25:741-756.
19. Vento M, Asensi M, Sastre J, Garcia-Sala F, Pallardo FV, Vina J:
Resuscitation with room air instead of 100% oxygen prevents
oxidative stress in moderately asphyxiated term neonates.
Pediatrics 2001, 107:642-647.
20. Vento M, Asensi M, Sastre J, Garcia-Sala F, Vina J: Six years of
experience with the use of room air for the resuscitation of
asphyxiated newly born term infants. Biol Neonate 2001, 79:
261-267.
21. Saugstad OD: The role of oxygen in neonatal resuscitation.
Clin Perinatol 2004, 23:431-443.
22. Tan A, Schulze A, O’Donnell CP, Davis AG: Cochrane Database
Syst Rev 2005, April 18 (2):CD002273.
23. Saugstad OD, Ramji S, Soll RF, Vento M: Resuscitation of
newborn infants with 21% or 100% oxygen: an updated sys-
tematic review and meta-analysis. Neonatology 2008, 94:176-
182.
24. Jacobson YG, Defalco AJ, Mundth ED, Keller MA: Hyperbaric
oxygen in the therapy of experimental hemorrhagic shock.
Surg Forum 1965, 16:15-17.
25. Torbati D, Parolla D, Lavy S: Organ blood flow, cardiac output,
arterial blood pressure, and vascular resistance in rats
exposed to various oxygen pressures. Aviat Space Environ
Med 1979, 50:256-263.
26. Onarheim J, Tyssebotn I: Effect of high ambient pressure and
oxygen tension on organ blood flow in anesthetized rats.
Undersea Biomed Res 1980, 7:47-60.
27. Busing CM, von Gerstenbergk L, Dressler P, Rumm D, Wentz K:
Experimental studies on microcirculation under normobaric
hyperoxia using the microspheres method. Exp Pathol 1981,
19:146-153.
28. Hordnes C, Tyssebotn I, Onarheim J: Effect of high ambient
pressure and oxygen tension on organ blood flow in con-
scious rats. Acta Physiol Scand 1982, 114:23A.
29. Matalon S, Nasarajah MS, Farhi LE: Pulmonary and circulatory
changes in conscious sheep exposed to 100% oxygen at 1
ATA. J Appl Physiol 1982, 53:110-116.
30. Plewes JL, Farhi LE: Peripheral circulatory responses to acute
hyperoxia. Undersea Biomed Res 1983, 10:123-129.
31. Hahnloser PB, Domanig E, Lanphier E, Shenk WG Jr.: Hyper-
baric oxygenation: alterations in cardiac output and regional
blood flow. J Thorac Cardiovasc Surg 1966, 52:223-231.
32. Bergo GW, Risberg J, Tyssebotn I: Effect of 5 bar oxygen on
cardiac output and organ blood flow in conscious rats. Under-
sea Biomed Res 1988, 15:457-470.
33. Kawamura M, Sakakibara K, Yusa T: Effect of increased oxygen
on the peripheral circulation in acute, temporary limb
ischemia. J Cardiovasc Surg 1978, 19:161-168.
34. Bitterman H, Brod V, Weiss G, Kushnir D, Bitterman N: The
effects of oxygen on regional hemodynamics in hemorrhagic
shock. Am J Physiol 1996, 40:H203-H211.
35. Waisman D, Brod V, Wolff R, Sabo E, Chernin M, Weintraub Z,
Rotschild A, Bitterman H: Effects of hyperoxia on local and
remote microcirculatory inflammatory response after
splanchnic ischemia and reperfusion. Am J Physiol 2003, 285:
H643-H652.
36. Barth E, Bassi G, Maybauer DM, Simon F, Groger M, Oter S,
Speit G, Nguyen CD, Hasel C, Moller P, Wachter U, Vogt JA,
Matejovic M, Radermacher P, Calzia E: Effects of ventilation
with 100% oxygen during early hyperdynamic porcine fecal
peritonitis. Crit Care Med 2008, 36:495-503.
37. Cason BA, Wisneski J, Neese RA, Stanley WC, Hickey RF,
Shnier CB, Gertz EW: Effects of high arterial oxygen tension
on function, blood flow distribution, and metabolism in
ischemic myocardium. Circulation 1992, 85:828-838.
38. Nathan C: Oxygen and the inflammatory cell. Nature 2003, 17:
675-676.
39. Lefer AM, Lefer DJ: Pharmacology of the endothelium in
ischemia-reperfusion and circulatory shock. Annu Rev Phar-
macol Toxicol 1993, 33:71-90.
40. Deitch EA: Gut failure: its role in the multiple organ failure
syndrome. In Multiple Organ Failure: Pathophysiology and Basic
Concepts of Therapy. Edited by Deitch EA. New York: Thieme
Medical Publisher; 1990:40-59.
41. Eppihimer MJ, Granger DN: Ischemia/reperfusion-induced
leukocyte-endothelial interactions in postcapillary venules.
Shock 1997, 8:16-25.
42. Buras J: Basic mechanisms of hyperbaric oxygen in the treat-
ment of ischemia-reperfusion injury. Int Anesthesiol Clin 2000,
38:91-109.
43. Sirsjö A, Lehr HA, Nolte D, Haapaniemi T, Lewis DH, Nylander G,
Messmer K: Hyperbaric oxygen treatment enhances the
recovery of blood flow and functional capillary density in
postischemic striated muscle. Circulatory Shock 1993, 40:9-
13.
44. Zamboni WA, Roth AC, Russell RC, Graham B, Suchy H, Kucan
JO:  Morphological analysis of the microcirculation during
reperfusion of ischemic skeletal muscle and the effect of
hyperbaric oxygen. Plast Reconstr Surg 1993, 91:1110-1123.
45. Tjärnström J, Wikström T, Bagge U, Risberg B, Braide M: Effects
of hyperbaric oxygen treatment on neutrophil activation and
pulmonary sequestration in intestinal ischemia-reperfusion in
rats. Eur Surg Res 1999, 31:147-154.
46. Kaelin CM, Im MJ, Myers RA, Manson PN, Hoopes JE: The
effects of hyperbaric oxygen in free flaps in rats. Arch Surg
1990, 125:607-609.
47. Sharifi M, Fares W, Abdel-Karim I, Koch M, Sopko J, Adler D:
Usefulness of hyperbaric oxygen therapy to inhibit restenosis
after percutaneous coronary intervention for acute myocar-
dial infarction or unstable angina pectoris. Am J Cardiol 2004,
93:1533-1535.
48. Yogaratnam JZ, Laden G, Madden LA, Seymour AM, Guvendik L,
Cowen M, Greenman J, Cale A, Griffin S: Hyprbaric oxygen: a
new drug in myocardial revascularization and protection?
Cardivasc Revasc Med 2006, 7:146-154.
49. Chen MF, Chen HM, Ueng SWN, Shyr MH: Hyperbaric oxygen
pre-treatment attenuates hepatic reperfusion injury. Liver
1998, 18:110-116.
50. Zinchuk VV, Khdorovsky MN, Maslakov DA: Influence of differ-
ent oxygen modes on the blood oxygen transport and prooxi-
dant-antioxidant status during hepatic ischemia/reperfusion.
Physiol Res 2003, 52:533-544.
51. Thom SR: Functional inhibition of leukocyte β β2 integrins by
hyperbaric oxygen in carbon monoxide-mediated brain injury
in rats. Toxicol Appl Pharmacol 1993, 123:248-256.
52. Chen Q, Banick PD, Thom SR: Functional inhibition of rat poly-
morphonuclear leukocyte B2 integrins by hyperbaric oxygen
is associated with impaired cGMP synthesis. J Pharmacol Exp
Ther 1996, 276:929-933.
53. Buras JA, Reenstra WR: Hyperbaric oxygen decreases
endothelial cell E-selectin protein expression in an in-vitro
model of ischemia/reperfusion. Ann Emerg Med 1998, 32:S17.
54. Sukhotnik I, Coran AG, Greenblatt R, Brod V, Mogilner J, Shiloni
E, Shaoul R, Bitterman H: Effect of 100% oxygen on E-selectin
expression, recruitment of neutrophils and enterocyte apop-
tosis following intestinal ischemia-reperfusion in a rat. Pediatr
Surg Int 2008, 24:29-35.
55. Buras JA, Stahl GL, Svoboda KS, Reenstra WR: Hyperbaric
Available online http://ccforum.com/content/13/1/205
Page 7 of 8
(page number not for citation purposes)oxygen down-regulates ICAM-1 expression induced by
hypoxia and hypoglycaemia: the role of eNOS. Am J Physiol
2000, 278:C292-C302.
56. Banick PD, Chen Q, Xu YA, Thom SR: Nitric oxide inhibits neu-
trophil  β β2 integrin function by inhibiting membrane-associ-
ated cyclic GMP synthesis. J Cell Physiol 1997, 172:12-24.
57. Mink RB, Dutka AJ: Hyperbaric oxygen after global cerebral
ischemia in rabbits does not promote brain lipid peroxidation.
Crit Care Med 1995, 23:1398-1404.
58. Sukhotnic I, Brod V, Lurie M, Rahat MA, Shnizer S, Lahat N,
Mogilner JG, Bitterman H: The effect of 100% oxygen on
intestinal preservation and recovery following ischemia-
reperfusion injury in rats. Crit Care Med, in press.
59. Akin ML, Gulluoglu BM, Uluutku H, Erenoglu C, Elbuken E, Yildirim
S, Celenk L: Hyperbaric oxygen improves healing in experi-
mental rat colitis. Undersea Hyperbar Med 2002, 29:279-285.
60. Rachmilewitz D, Karmeli F, Okon E, Rubenstein I, Better O:
Hyperbaric oxygen: a novel modality to ameliorate experi-
mental colitis. Gut 1998, 43:512-518.
61. Lavy A, Weisz G, Adir Y, Ramon Y, Melamed Y, Eidelman S:
Hyperbaric oxygen for perianal Crohn’s disease. J Clin Gas-
troenterol 1994, 19:202-205.
62. Sumen G, Cimsit M, Eroglu L: Hyperbaric oxygen treatment
reduces carrageenan-induced acute inflammation in the rat.
Eur J Pharmacol 2001, 431:265-268.
63. Luongo C, Imperatore F, Cuzzocrea S, Fillipelli A, Scafuro MA,
Mangoni G, Portolano F, Rossi F: Effects of hyperbaric oxygen
exposure on a zymosan-induced shock model. Crit Care Med
1998, 26:1972-1986.
64. Imperatore F, Cuzzocrea S, Luongo C, Liguori G, Scafuro A, De
Angelis A, Rossi F, Caputi AP, Filippelli A: Hyperbaric oxygen
therapy prevents vascular derrangements during zymosan-
induced multiple-organ-failure syndrome. Int Care Med 2004,
30:1175-1181.
65. Lahat N, Rahat MA, Ballan M, Weiss-Cerem L, Engelmayer M, Bit-
terman H: Hypoxia reduces CD80 expression on monocytes,
but enhances their LPS-stimulated TNFα α secretion. J Leuko-
cyte Biol 2003, 74:197-2005.
66. Daniliuc S, Bitterman H, Rahat MA, Kinarty A, Rosenzweig D,
Lahat N: Hypoxia inactivates inducible nitric oxide synthase in
mouse macrophages by disrupting its interaction with alpha-
actinin 4. J Immunol 2003, 171:5631-5640.
67. Rahat MA, Marom B, Bitterman H, Weiss-Cerem L, Kinarty A,
Lahat N: Hypoxia reduces the output of matrix metallopro-
teinase-9 (MMP-9) in monocytes by inhibiting its secretion
and elevating membranal association. J Leukocyte Biol 2006,
79:706-718.
68. Lahat N, Rahat MA, Kinarty A, Weiss-Cerem L, Pinchevski L, Bit-
terman H: hypoxia enhances lysosomal TNFα α degradation in
mouse peritoneal macrophages. Am J Physiol 2008 295:C2-
C12.
69. Thiel M, Caldwell CC, Kreth S, Kuboki S, Chen P, Smith P, Ohta
A, Lentsch AB, Lukashev D, Sitkovsky MV: Targeted deletion of
HIF-1alpha gene in T cells prevents their inhibition in hypoxic
inflamed tissues and improves septic mice survival. PLoS
ONE 2007, 2:e853.
70. Thiel M, Chouker A, Ohta A, Jackson E, Caldwell C, Smith P, Luka-
shev D, Bittmann I, Sitkovsky MV: Oxygenation inhibits the physi-
ological tissue-protecting mechanism and thereby exacerbates
acute inflammatory lung injury. PLoS Biol 2005, 3:e174.
71. Waisman D, Brod V, Weber G, Lavon O, Popovski F, Vasilenko I,
Rahat MA, Lahat N, Bitterman H: Dose-related effects of hyper-
oxia on the pulmonary inflammatory response in sepsis
induced by cecal ligation and puncture. Shock 2006, 25:S54.
72. Buras JA, Holt D, Orlow D, Belikoff B, Pavlides S, Reenstra WR:
Hyperbaric oxygen protects from sepsis mortality via an IL-10-
dependent mechanism. Crit Care Med 2006, 34:2624-2629.
73. Brummelkamp WH, Hogendijk JL, Boerema I: Treatment of
anaerobic infections (clostridial myositis) by drenching the
tissues with oxygen under high atmospheric pressure.
Surgery 1961, 4:299-302.
74. Slack WK, Thomas DA, Perrins D: Hyperbaric oxygenation in
chronic osteomyelitis. Lancet 1965, 1:1093-1094.
75. Park M: Effects of hyperbaric oxygen in infectious diseases:
basic mechanisms. In  Hyperbaric Medicine Practice. 2nd
edition. Edited by Kindwall EP, Whelan HT. Flagstaff, AZ: Best
Publishing Company; 1999:205-243.
76. Mathieu D, Wattel F: Physiologic effects of hyperbaric oxygen
on microorganisms and host defences against infection. In
Handbook on Hyperbaric Medicine. Edited by Mathieu D. Dor-
drecht, The Netherlands: Springer; 2006:103-119.
77. Silver IA: Cellular microenvironment in healing and non-
healing wounds. In Soft and Hard Tissue Repair. Edited by Hunt
TK, Heppenstall RB, Pines M. New York: Praeger; 1984:50-66.
78. Gimbel ML, Hunt TK: Wound healing and hyperbaric oxygena-
tion. In  Hyperbaric Medicine Practice. 2nd edition. Edited by
Kindwall EP, Whelan HT. Flagstaff, AZ: Best Publishing
Company; 1999:169-204.
79. Calzia E, Oter S, Muth CM, Radermacher P: The evolving career
of hyperbaric oxygen in sepsis: from augmentation of O2
delivery to the modulation of the immune response. Crit Care
Med 2006, 34:2693-2695.
80. Greif R, Akca O, Horn EP, Kurz A, Sessler DI: Supplemental
perioperative oxygen to reduce the incidence of surgical-
wound infection. N Engl J Med 2000, 342:161-167.
81. Belda J, Aguilera L, de la Asuncion JG, Alberti J, Vicente R, Fer-
nandiz L, Rodriguez R, Company B, Sessler DI, Aguilar G, Botello
SG, Orti R: Supplemental perioperative oxygen and the risk of
surgical wound infection, a randomized controlled study. J
Am Med Assoc 2005, 294:2035-2042.
82. Pryor KO, Fahey TJ, Lien CA, Goldstein PA: Surgical site infec-
tion and the routine use of perioperative hyperoxia in a
general surgical population. J Am Med Assoc 2004, 291:79-
87.
83. Cairney WJ: Effect of hyperbaric oxygen on certain growth
features of Candida albicans. Aviat Space Environ Med 1978,
49:956-958.
84. Gudewicz TM, Mader JT, Davis CP: Combined effects of hyper-
baric oxygen and antifungal agents on the growth of Candida
albicans. Aviat Space Environ Med 1987, 58:673-678.
85. Ferguson BJ, Mitchell TG, Moon R, Camporesi EM, Farmer J:
Adjunctive hyperbaric oxygen for treatment of rhinocerebral
mucormycosis. Rev Infect Dis 1988, 10:551-559.
86. Guevara N, Roy D, Dutruc-Rosset C, Santini J, Hofman P, Castillo
L: Mucormycosis – early diagnosis and treatment. Rev Laryn-
gol Otol Rhinol (Bord) 2004, 125:127-131.
87. Yohai RA, Bullock JD, Aziz AA, Markert RJ: Survival factors in
rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994,
39:3-22.
88. Bitterman N, Bitterman H: Oxygen toxicity. In  Handbook on
Hyperbaric Medicine. Edited by Mathieu D. Dordrecht, The
Netherlands: Springer; 2006:731-766.
89. Fisher AB: Oxygen therapy, side effects and toxicity. Am Rev
Respir Dis 1980, 122:61-69.
90. Clark JM, Lambertsen CJ: Pulmonary oxygen toxicity: a review.
Parmacol Rev 1971, 23:37-133.
91. Lembertsen CJ: Effects of hyperoxia on organs and their
tissues. In  Lung Biology in Health and Disease. Volume 8.
Edited by Lenfant C. New York: Marcel Dekker; 1978:239-303.
92. Clark JM, Lambertsen CJ: Rate of development of pulmonary
oxygen toxicity in man during oxygen breathing at 2.0 ATA. J
Appl Physiol 1971, 30:739-752.
93. Clark JM, Jackson RM, Lambertsen CJ, Gelfand R, Hiller WD,
Unger M: Pulmonary function in men after oxygen breathing
at 3.0 ATA for 3.5 h. J Appl Physiol 1991, 71:878-885.
94. Huber GL, Drath DB: Pulmonary oxygen toxicity. In Oxygen and
Living Processes. Edited by Gilbert DL. New York: Springer-
Verlag; 1981:273-342.
95. Small A: New perspectives on hyperoxic pulmonary toxicity –
a review. Undersea Biomed Res 1984, 11:1-24.
96. Bitterman N: CNS oxygen toxicity. Undersea Hyperbar Med
2004, 31:63-72.
97. Raday-Bitterman N, Conforti N, Harel D, Lavy S: Analysis of pre-
seizure EEG changes in rats during hyperbaric oxygenation.
Exp Neurol 1975, 46:9-19.
98. Geva A, Kerem DH: Forecasting generalized epileptic seizure
from the EEG signal by wavelet analysis and dynamic unsu-
pervised fuzzy clustering. IEEE Trans Biomed Eng 1998,
45:1205-1216.
99. Clark JM: Effects of acute and chronic hypercapnia on oxygen
tolerance in rats. J Appl Physiol 1981, 50:1036-1044.
100. Arieli R, Ertracht O: Latency to CNS oxygen toxicity in rats as a
function of PCO2 and PO2. Eur J Appl Physiol Occup Physiol
1999, 80:598-603.
Critical Care    Vol 13 No 1 Bitterman
Page 8 of 8
(page number not for citation purposes)